Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

72.17 -1.94 (-2.62%)

Streaming Delayed Price Updated: 10:06 AM EDT, Jul 14, 2026 Add to My Watchlist

Price and Volume

Volume	188,728
Open	74.42
Bid (Size)	72.12 (100)
Ask (Size)	72.50 (100)
Prev. Close	74.11
Today's Range	72.11 - 75.33
52wk Range	14.30 - 87.83
Shares Outstanding	105,736,200
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

June 22, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

June 18, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Performance

YTD	+6.5%	+6.5%
1 Month	-6.5%	-6.5%
3 Month	+13.1%	+13.1%
6 Month	+9.5%	+9.5%
1 Year	+287.8%	+287.8%

More News

Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction ↗

June 05, 2026

Via MarketBeat

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Soars 70% After Hours on REDEMPLO Launch Momentum and Strong Q2 Earnings Beat ↗

May 07, 2026

Via Chartmill

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Presents a High-Growth, Technical Breakout Opportunity ↗

February 20, 2026

Via Chartmill

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

June 02, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

May 27, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

May 26, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum ↗

May 20, 2026

Via MarketBeat

Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near ↗

May 14, 2026

Via MarketBeat

Arrowhead (ARWR) Q2 2026 Earnings Transcript ↗

May 08, 2026

Via The Motley Fool

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

May 07, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

May 05, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

May 04, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)

May 01, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

What's going on in today's after hours session ↗

April 29, 2026

Via Chartmill

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

April 24, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results

April 20, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Emerges as a Growth Stock with a Constructive Technical Setup ↗

April 11, 2026

Via Chartmill

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo

March 28, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics

March 26, 2026

Via MarketMinute

Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data

March 26, 2026

Via MarketMinute

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

February 24, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

February 17, 2026

Via Investor Brand Network

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

February 17, 2026

From BioMedWire

Via GlobeNewswire

Frequently Asked Questions

Is Arrowhead Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Arrowhead Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Arrowhead Pharmaceuticals, Inc. - Common Stock trade on?

Arrowhead Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock is ARWR on the Nasdaq Stock Market

What is the current price of Arrowhead Pharmaceuticals, Inc. - Common Stock?

The current price of Arrowhead Pharmaceuticals, Inc. - Common Stock is 72.17

When was Arrowhead Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Arrowhead Pharmaceuticals, Inc. - Common Stock was at 07/14/26 10:06 AM ET

What is the market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock is 7.63B

How many shares of Arrowhead Pharmaceuticals, Inc. - Common Stock are outstanding?

Arrowhead Pharmaceuticals, Inc. - Common Stock has 8B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.